Image

Empowering Hispanic Patients' Lung Cancer Screening Uptake (Empower Latinx)

Recruiting
50 - 80 years of age
Both
Phase N/A

Powered by AI

Overview

The Hispanic/Latinx community (hereafter Hispanic) is the country's second-largest racial/ethnic group, accounting for 19.1% of the total population. However, they remain one of the most underserved populations with suboptimal access to healthcare and screening services due to low income, lack of health insurance, perceived discrimination, language barriers, and limited health literacy. Lung cancer is the leading cause of cancer related mortality with 1.8 million annual deaths worldwide, with Hispanic patients known to have lower survival rates compared with non-Hispanic whites. Lung cancer screening (LCS) with low dose computed tomography (LDCT) decreases this mortality rate of lung cancer by 20%. Yet many Latinx patients who are eligible for lung cancer screening are still falling through the cracks which prevents patients the ability to detect lung cancer early. This study will test and compare the effect of a multi-level intervention on ordering LDCT within 4 months after patient enrollment to those in an Enhanced Usual Care. Our proposed intervention includes:

  • Primary care provider notifications of patients' LCS eligibility;
  • Patients' education;
  • Patients' referral to financial navigation resources;
  • Patients' reminder to discuss LCS during primary care provider (PCP) visit.

Eligibility

Inclusion Criteria:

  • Aged 50- 80 years of age.
  • Be able to speak English and Spanish
  • Must have a scheduled appointment with their Primary Care Providers within next one to three months.
  • The Scheduled PCP appointment is at any of the 4 University of California Irvine Health (UCI Health) primary care clinics in Orange County including two UCI federally qualified health centers
  • History of 20-pack year smoking history ( based on survey self-report)
  • Current smoker or a former smoker who has quit smoking within the last 15 years (based on survey self-report)

Exclusion Criteria:

  • Prior history of lung cancer
  • Chest CT for any reason in the last 12 months based on self-report and UCI EMR
  • History of Alzheimer's disease or dementia

Study details

Lung Cancer

NCT06225414

University of California, Irvine

7 March 2024

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.